NCT05296421 Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
| NCT ID | NCT05296421 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2022-03-14 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 16 participants in total. It began in 2022-03-14 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.
Eligibility Criteria
Inclusion Criteria: * Male or female patients \>= 18 years of age * Pancreatic adenocarcinoma patients, previously diagnosed by biopsy, who are candidates for intended curative resection either with or without neoadjuvant chemotherapy * Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed pancreatectomy * 16 patients will be enrolled including 8 with no prior treatment and 8 treated with at least 3 months of neoadjuvant chemotherapy * All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry Exclusion Criteria: * Patients receiving any anti-cancer therapy (chemotherapy, immunotherapy, and/or biologic therapy) for 8 patients; the other 8 patients will be treated with neoadjuvant chemotherapy but no radiation, biologic or immunotherapy prior to surgery * Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study * Concomitant active malignancy * Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)
Contact & Investigator
Howard S Hochster, MD
PRINCIPAL INVESTIGATOR
Rutgers Cancer Institute of New Jersey
Frequently Asked Questions
Who can join the NCT05296421 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05296421 currently recruiting?
Yes, NCT05296421 is actively recruiting participants. Contact the research team at howard.hochster@rutgers.edu for enrollment information.
Where is the NCT05296421 trial being conducted?
This trial is being conducted at Livingston, United States, New Brunswick, United States.
Who is sponsoring the NCT05296421 clinical trial?
NCT05296421 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Howard S Hochster, MD at Rutgers Cancer Institute of New Jersey. The trial plans to enroll 16 participants.